Malignant tumors of the nose and paranasal sinuses: a retrospective review of a Portuguese cancer center’s experience

Cover Page

Cite item

Full Text

Abstract

Introduction. Although uncommon from a population-based perspective, there is considerable morbidity and mortality associated with malignant tumors of the nose and paranasal sinuses.

The objective of this study was to characterize the presentation, risk factors, management and survival of patients with these tumors treated at a single institution.

Materials and methods. We retrospectively reviewed the clinical records of patients with malignancies of the nose and paranasal sinuses diagnosed between January 2010 and December 2014 at a tertiary cancer center. Univariate and multivariate analysis were performed.

Results. Ninety patients were included in the study. Mean age at diagnosis was 62.8 years (range, 2–95 years) and mean follow-up was 44.5 months (range, 2–113 months). The maxillary sinus (33.3 %) and the nasal cavity (32.2 %) were the most frequent sites of origin. Squamous cell carcinoma (36.7 %), mucosal melanoma (15.6 %) and adenoid cystic carcinoma (10 %) were the most common histologic subtypes. Surgery was the primary treatment for 86.7 % of patients. Recurrence occurred in 45 patients (50 %). The overall 5‑year survival was 39.3 % and disease free-survival was 45.9 %. Survival was significantly decreased in non-smokers (p = 0.022), T3–4 tumors (p = 0.007), positive lymph nodes (p <0.001), nonepithelial tumors (p = 0.036) and positive margins (p = 0.032). Survival was not affected by surgical approach between endoscopic, open and combined approaches (p = 0.088).

Conclusion. Prognosis is poor, with high recurrences and low survival, but clearly histology, location and stage-dependent. Sound oncologic principles, with complete resections and negative margins, result in a better outcome.

About the authors

L. G. Castelhano

Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental R

Author for correspondence.
Email: lmgcastelhano@gmail.com
ORCID iD: 0000-0001-6501-6941

Department of Otolaryngology

126 R. da Junqueira, Lisboa 1349–019

Portugal

F. A. Correia

Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental R

Email: fake@neicon.ru

Department of Otolaryngology

126 R. da Junqueira, Lisboa 1349–019

Portugal

D. F. Raposo

Hospital Prof. Doutor Fernando Fonseca

Email: fake@neicon.ru
ORCID iD: 0000-0001-9337-0737

Department of Otolaryngology

IC19, Amadora 2720–276, Portugal

Portugal

A. H. Campos

Hospital CUF Tejo

Email: fake@neicon.ru

Department of Otolaryngology

Av. 24 de Julho 171A, 1350–352 Lisboa

Portugal

M. R. Melo

Hospital Prof. Doutor Fernando Fonseca

Email: fake@neicon.ru

Department of Otolaryngology

IC19, Amadora 2720–276

Portugal

S. A. Pereira

Hospital de São José, Centro Hospitalar Universitário de Lisboa Central

Email: fake@neicon.ru
ORCID iD: 0000-0002-8341-078X

Department of Otolaryngology

R. José António Serrano, Lisboa 1150–199

Portugal

M. C. Mariano

Hospital de São José, Centro Hospitalar Universitário de Lisboa Central

Email: fake@neicon.ru
ORCID iD: 0000-0002-6898-9631

Department of Otolaryngology

R. José António Serrano, Lisboa 1150–199

Portugal

L. Ferreira

Instituto Português de Oncologia Francisco Gentil

Email: fake@neicon.ru
ORCID iD: 0000-0001-7268-7495

Department of Otolaryngology

R. Prof. Lima Basto, Lisboa 1099–023

Portugal

P. Montalvão

Instituto Português de Oncologia Francisco Gentil

Email: fake@neicon.ru

Department of Otolaryngology

R. Prof. Lima Basto, Lisboa 1099–023

Portugal

M. T. Magalhães

Instituto Português de Oncologia Francisco Gentil

Email: fake@neicon.ru

Department of Otolaryngology

R. Prof. Lima Basto, Lisboa 1099–023

Portugal

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.